TFEB and fatty liver disease: Despite the absence of hepatic steatosis after 1-week WD challenge (Supplementary Figs. 5a, b), hepatic β-hydroxybutyrate, a marker of fatty acid oxidation, was higher in TFEB overexpression groups (Fig. 4c).